Kodiak Sciences: The Revolution in Ophthalmology?
Reading Time: 4 minutes
Kodiak Sciences is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of chronic, prevalent retinal diseases that are one of the leading causes of blindness. The company's proprietary Antibody-Biopolymer Conjugate (ABC) platform is designed to maintain a longer and more effective drug concentration in ocular tissue compared to currently available biologics for retinal diseases. Kodiak Sciences (NASDAQ: KOD) is a biopharmaceutical company based in Palo Alto, California. It operates in the highly...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
